Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06497673

Sanger Human Cell Atlasing Project

"Cell Atlasing" refers to a novel strategy to characterise cells in tissues at the molecular level in a quantitative manner. The international Human Cell Atlas consortium brings together a community of biologists, clinicians, technologists, physicists, computational scientists, software engineers, and mathematicians to capitalise on drawing together leaders with various biological, technical and computational expertise. The project is based on the aim to define all human cell types in terms of their distinctive patterns of gene expression, physiological states, developmental trajectories, and location. This will pave the way to create a reference map of all human cells as a basis for understanding human health and diagnosing, monitoring, and treating disease.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Wellcome Sanger Institute

Cambridge, United Kingdom

About this study

Previous methods for quantifying molecular states of cells included microarray and standard RNA-seq analysis on a tissue section (RNA-seq is a technique to look at the activity of all the genes in a cell). These methods estimate the activity of any given gene by averaging the signal from millions of cells. Given the heterogeneity of cell populations (i.e.how uniform they are), measurement of the mean values of signals overlooks the internal interactions and differences within a cell population that may be crucial for maintaining normal tissue function and facilitating disease progression.

The Sanger Human Cell Atlasing project will adopt various genomic approaches that will provide genome-wide information in a single experiment. This project aims to scale up the single cell genomics and high-throughput highly multiplex spatial gene expression profiling approaches. Coupled with powerful computational methods, this strategy will produce a comprehensive and systematic reference map of human cells, providing a fundamental blueprint of cell states for both basic biological research and clinical practice.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Samples are from the living and the deceased age 0 to 99+ from healthy and diseased individuals.
  • All samples will have fully informed consent for use in research.

Exclusion criteria

  • Samples taken without consent for use in future research
  • Samples taken from individuals without the capacity to consent to use in research

Treatment and study plan

Sample collection

Other

New collected samples, as well as surplus surgical and diagnostic samples.

Primary outcomes

  1. This project aims to scale up the single cell genomics and high-throughput highly multiplex spatial gene expression profiling approaches.

    Time frame: 10 years

    Coupled with powerful computational methods, this strategy will produce a comprehensive and systematic reference map of human cells, providing a fundamental blueprint of cell states for both basic biological research and clinical practice.

Sponsors and collaborators

Lead sponsor

The Wellcome Sanger Institute

Other

Registry information

Official study title

Sanger Human Cell Atlasing Project. Defining Human Cells in Terms of Gene Expression, Physiological States,Developmental Trajectories, and Location.

Acronym: HCA

Important dates

Study start
2019
Primary completion
2029
Study completion
2029
First posted
Jul 12, 2024
Registry last updated
Jul 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.